• The partners target more than 10 metric tons after GRAS and over 200 metric tons a year at longer-term scale.

• Strive will test the protein in FREEMILK and other nutrition products as Dyadic and BRIG BIO optimize production.

Dyadic Applied BioSolutions, a Jupiter, Florida-based biotechnology company listed on Nasdaq, said Nov. 10 it is working with Netherlands-based BRIG BIO and Wichita, Kansas-based Strive Nutrition to develop, scale and potentially commercialize precision-fermented bovine alpha-lactalbumin. The protein is intended for Strive’s FREEMILK platform and other nutrition products.

The collaboration combines Dyadic’s Dapibus microbial production platform with BRIG BIO’s precision-fermentation commercialization and regulatory capabilities. Dyadic and BRIG BIO will optimize the strain and process around productivity, product quality and manufacturing economics, while Strive will assess protein samples in formulations and application testing. The companies describe the work as a pathway from development through manufacturing and commercial supply.

The parties are targeting initial availability of more than 10 metric tons after completion of a self-affirmed generally recognized as safe process, followed by annual production above 200 metric tons at longer-term scale. GRAS completion is targeted for early 2028, and any supply agreement remains conditional on technical development, regulatory readiness, quality qualification and a successful commercial evaluation.

The new arrangement adds a prospective product customer to a December 2025 development and commercialization agreement between Dyadic and BRIG BIO. Under that earlier deal, BRIG BIO agreed to fund development and receive a global commercial license to production strains, while Dyadic would receive access and milestone payments plus shared revenue tied to sales. Dyadic executives framed Strive’s involvement as a test of that commercialization model.

“Our work with BRIG BIO and the opportunity with Strive demonstrate how that model can create a pathway from technology development toward potential commercial demand.”

Joe Hazelton, president and chief operating officer, Dyadic Applied BioSolutions